Roxana Elena Bohiltea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Roxana Elena Bohiltea has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- Florentina Furtunescu
Department of Public Health and Management, Carol Davila University of Medicine and Pharmacy, Romania
14 shared publications - Bianca-Margareta Salmen
Doctoral School, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
12 shared publications Octavian Munteanu
Department of Anatomy, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
12 shared publications- Radu Vladareanu
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
10 shared publications - Corina Grigoriu
Department of Obstetrics and Gynecology, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
9 shared publications Costin Berceanu
Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
9 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by MDPI AG in Romanian Journal of Preventive Medicine
- Vol. 4 (3) , 10
Advancing Preventive Medicine: Highlights from the Second International Congress of Preventive Medicine
This article presents the report of the Second International Congress of Preventive Medicine, organized by the Romanian Society of Preventive Medicine (SRMP) between 19–21 March 2026 in Bucharest, Romania. The congress brought together experts from oncology, public health, genetics, neonatology, reproductive medicine, pediatrics, psychiatry, nutrition, dentistry, family medicine, and other medical specialties to discuss current advances and future directions in preventive healthcare. The scientific program emphasized the transition from reactive healthcare models toward predictive, personalized, and prevention-oriented medicine. Key topics included implementation of national screening programs, cancer prevention and early diagnosis, vaccination strategies, lifestyle medicine, pediatric nutrition, oral health, reproductive prevention, fertility preservation, mental health promotion, addiction prevention, neonatal screening, and oncogenetics. Particular attention was given to risk stratification, early detection of disease, multidisciplinary collaboration, health literacy, and the integration of emerging technologies, including artificial intelligence, into preventive healthcare pathways. Across all sessions, speakers highlighted the importance of evidence-based policies, coordinated healthcare infrastructures, and sustainable prevention programs capable of translating scientific advances into measurable population health benefits. The congress reinforced the central role of prevention in addressing contemporary healthcare challenges and improving long-term health outcomes across the lifespan.
- 17 September 2026
- Published by MDPI AG in Romanian Journal of Preventive Medicine
- Vol. 4 (3) , 10
Open AccessAdvancing Preventive Medicine: Highlights from the Second International Congress of Preventive Medicine
This article presents the report of the Second International Congress of Preventive Medicine, organized by the Romanian Society of Preventive Medicine (SRMP) between 19–21 March 2026 in Bucharest, Romania. The congress brought together experts from oncology, public health, genetics, neonatology, reproductive medicine, pediatrics, psychiatry, nutrition, dentistry, family medicine, and other medical specialties to discuss current advances and future directions in preventive healthcare. The scientific program emphasized the transition from reactive healthcare models toward predictive, personalized, and prevention-oriented medicine. Key topics included implementation of national screening programs, cancer prevention and early diagnosis, vaccination strategies, lifestyle medicine, pediatric nutrition, oral health, reproductive prevention, fertility preservation, mental health promotion, addiction prevention, neonatal screening, and oncogenetics. Particular attention was given to risk stratification, early detection of disease, multidisciplinary collaboration, health literacy, and the integration of emerging technologies, including artificial intelligence, into preventive healthcare pathways. Across all sessions, speakers highlighted the importance of evidence-based policies, coordinated healthcare infrastructures, and sustainable prevention programs capable of translating scientific advances into measurable population health benefits. The congress reinforced the central role of prevention in addressing contemporary healthcare challenges and improving long-term health outcomes across the lifespan.
- Open Access
- 31 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6865
Ureaplasma Species in Perinatal Disease: From the Age of Innocence to the Missing Villain
Ureaplasma urealyticum and Ureaplasma parvum occupy an odd place in perinatal medicine: dismissed for decades as harmless residents of the female genital tract, they are now recognized as pathogens with real consequences for preterm newborns. This review traces that paradigm shift, from organisms once dismissed as harmless colonizers to pathogens now implicated in chorioamnionitis, preterm birth, and a range of serious neonatal morbidities, and describes the molecular mechanisms that underlie their pathogenicity: Toll-like receptor (TLR1/2/6/9)-mediated NF-κB and MyD88/IRAK4/TRAF6 signaling, NLRP3 inflammasome activation and pyroptosis, and blood–brain barrier disruption via claudin-5/occludin downregulation and MMP-mediated tight junction cleavage. We also review the evidence for biofilm-conferred antibiotic tolerance and the clinical associations between Ureaplasma colonization and intraventricular hemorrhage (pooled OR 1.62, 95% CI 1.23–2.13), bronchopulmonary dysplasia (pooled OR 2.30, 95% CI 1.65–3.20), late-onset sepsis, and neurodevelopmental impairment. Diagnosis remains a weak point: culture sensitivity is below 10% compared with polymerase chain reaction (PCR) testing, and no randomized trial has yet shown that microbiological eradication translates into better clinical outcomes—a gap we examine critically. Whether these organisms cause disease seems to depend on gestational age, bacterial load, serovar-specific virulence, and host immune competence. We argue that this conditionality calls for risk stratification rather than dismissal whenever Ureaplasma is identified in clinical specimens, and that the field needs a paradigm shift toward Ureaplasma screening in high-risk pregnancies and targeted neonatal PCR testing, backed by adequately powered interventional trials.
- 31 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6865
Open AccessUreaplasma Species in Perinatal Disease: From the Age of Innocence to the Missing Villain
Ureaplasma urealyticum and Ureaplasma parvum occupy an odd place in perinatal medicine: dismissed for decades as harmless residents of the female genital tract, they are now recognized as pathogens with real consequences for preterm newborns. This review traces that paradigm shift, from organisms once dismissed as harmless colonizers to pathogens now implicated in chorioamnionitis, preterm birth, and a range of serious neonatal morbidities, and describes the molecular mechanisms that underlie their pathogenicity: Toll-like receptor (TLR1/2/6/9)-mediated NF-κB and MyD88/IRAK4/TRAF6 signaling, NLRP3 inflammasome activation and pyroptosis, and blood–brain barrier disruption via claudin-5/occludin downregulation and MMP-mediated tight junction cleavage. We also review the evidence for biofilm-conferred antibiotic tolerance and the clinical associations between Ureaplasma colonization and intraventricular hemorrhage (pooled OR 1.62, 95% CI 1.23–2.13), bronchopulmonary dysplasia (pooled OR 2.30, 95% CI 1.65–3.20), late-onset sepsis, and neurodevelopmental impairment. Diagnosis remains a weak point: culture sensitivity is below 10% compared with polymerase chain reaction (PCR) testing, and no randomized trial has yet shown that microbiological eradication translates into better clinical outcomes—a gap we examine critically. Whether these organisms cause disease seems to depend on gestational age, bacterial load, serovar-specific virulence, and host immune competence. We argue that this conditionality calls for risk stratification rather than dismissal whenever Ureaplasma is identified in clinical specimens, and that the field needs a paradigm shift toward Ureaplasma screening in high-risk pregnancies and targeted neonatal PCR testing, backed by adequately powered interventional trials.
- Open Access
- 28 November 2025
- Published by MDPI AG in Romanian Journal of Preventive Medicine
- Vol. 3 (1) , 4
Biomarkers and Early Detection Strategies for Ovarian Tumors
Ovarian cancer is a highly aggressive disease with a poor prognosis, largely due to challenges in early detection. Traditional screening methods, including transvaginal ultrasound (TVS) and CA125 testing, have notable limitations in detecting early-stage disease and are not advised for widespread use. This article examines emerging early detection technologies, such as novel biomarkers, circulating DNA, PCR assays from Pap swabs, autoantibodies, microRNAs, and advanced imaging techniques. Future advancements in therapeutic methods may enhance survival outcomes linked to early detection. While general population screening remains unendorsed, targeted screening might be valuable for high-risk groups, such as those with Lynch syndrome, but should not replace risk-reducing surgeries. Developing comprehensive screening guidelines for high-risk individuals is essential for improving early detection and survival rates in ovarian cancer.
- 28 November 2025
- Published by MDPI AG in Romanian Journal of Preventive Medicine
- Vol. 3 (1) , 4
Open AccessBiomarkers and Early Detection Strategies for Ovarian Tumors
Ovarian cancer is a highly aggressive disease with a poor prognosis, largely due to challenges in early detection. Traditional screening methods, including transvaginal ultrasound (TVS) and CA125 testing, have notable limitations in detecting early-stage disease and are not advised for widespread use. This article examines emerging early detection technologies, such as novel biomarkers, circulating DNA, PCR assays from Pap swabs, autoantibodies, microRNAs, and advanced imaging techniques. Future advancements in therapeutic methods may enhance survival outcomes linked to early detection. While general population screening remains unendorsed, targeted screening might be valuable for high-risk groups, such as those with Lynch syndrome, but should not replace risk-reducing surgeries. Developing comprehensive screening guidelines for high-risk individuals is essential for improving early detection and survival rates in ovarian cancer.
- Open Access
- 14 June 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (12) , 1514
Neurological Outcomes in Late Preterm Infants: An Updated Review of Recent Research and Clinical Insights
Research on late preterm infants is limited compared with extremely low birth weight infants, despite their vulnerability to brain injury. Early intervention is crucial, as these infants often face higher risks of cerebral palsy and developmental delays. This review examines methods to predict neurological outcomes and evaluates standard care protocols for neurologically affected late preterm infants. It also explores the potential for developing a comprehensive care bundle that integrates family involvement and delineates the responsibilities for continuous developmental monitoring. A total of 21 studies, primarily cohort studies, were included. This review synthesizes recent research on neurological development in late preterm infants, highlighting key markers and methods to improve neurological monitoring and long-term outcomes. Late preterm infants are at an increased risk for neurodevelopmental impairments, such as cerebral palsy and cognitive delays, particularly when growth restrictions or low birth weight are present. Early interventions, including specialized neurological assessments and targeted rehabilitation, show potential for improving these outcomes. Late preterm infants face increased neurodevelopmental risks despite low perinatal mortality. Early identification, standardized assessments, and targeted follow-up are essential. Emerging interventions show promise, but further research and equitable care access are needed to improve long-term outcomes.
- 14 June 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (12) , 1514
Open AccessNeurological Outcomes in Late Preterm Infants: An Updated Review of Recent Research and Clinical Insights
Research on late preterm infants is limited compared with extremely low birth weight infants, despite their vulnerability to brain injury. Early intervention is crucial, as these infants often face higher risks of cerebral palsy and developmental delays. This review examines methods to predict neurological outcomes and evaluates standard care protocols for neurologically affected late preterm infants. It also explores the potential for developing a comprehensive care bundle that integrates family involvement and delineates the responsibilities for continuous developmental monitoring. A total of 21 studies, primarily cohort studies, were included. This review synthesizes recent research on neurological development in late preterm infants, highlighting key markers and methods to improve neurological monitoring and long-term outcomes. Late preterm infants are at an increased risk for neurodevelopmental impairments, such as cerebral palsy and cognitive delays, particularly when growth restrictions or low birth weight are present. Early interventions, including specialized neurological assessments and targeted rehabilitation, show potential for improving these outcomes. Late preterm infants face increased neurodevelopmental risks despite low perinatal mortality. Early identification, standardized assessments, and targeted follow-up are essential. Emerging interventions show promise, but further research and equitable care access are needed to improve long-term outcomes.
- Open Access
- 26 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3022
Investigating the Role of Skin Autofluorescence in Gestational Diabetes Mellitus: A Systematic Review
Gestational diabetes mellitus (GDM) is a pregnancy-specific condition that can cause serious complications for both the mother and the fetus. Preventing these complications requires optimum glycemic control. Skin autofluorescence (SAF) is a non-invasive and innovative method that evaluates the levels of advanced glycation end products, markers of hyperglycemia, that could aid in the optimum management of GDM-complicated pregnancies. This systematic review aims to assess SAF’s potential utility in the prediction of short-term and long-term outcomes in GDM. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology, with the protocol identifier CRD42024559012, we used “(skin autofluorescence OR SAF) AND (gestational diabetes mellitus OR GDM)” as a search criterion on the PubMed, Scopus, and Web of Science databases. After a rigorous selection process, we included five articles, which evaluated SAF values and GDM, SAF and pregnancies complicated by diabetes mellitus, and SAF and macrosomia. GDM diagnosis varies due to the different approaches among the major guidelines, leading to variations in interpretation and diagnostic thresholds. Across studies, this variability contributes to inconsistent SAF values. As a standardized and objective marker, SAF could provide a uniform criterion, improving GDM management. Further research is needed to validate its clinical utility.
- 26 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3022
Open AccessInvestigating the Role of Skin Autofluorescence in Gestational Diabetes Mellitus: A Systematic Review
Gestational diabetes mellitus (GDM) is a pregnancy-specific condition that can cause serious complications for both the mother and the fetus. Preventing these complications requires optimum glycemic control. Skin autofluorescence (SAF) is a non-invasive and innovative method that evaluates the levels of advanced glycation end products, markers of hyperglycemia, that could aid in the optimum management of GDM-complicated pregnancies. This systematic review aims to assess SAF’s potential utility in the prediction of short-term and long-term outcomes in GDM. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology, with the protocol identifier CRD42024559012, we used “(skin autofluorescence OR SAF) AND (gestational diabetes mellitus OR GDM)” as a search criterion on the PubMed, Scopus, and Web of Science databases. After a rigorous selection process, we included five articles, which evaluated SAF values and GDM, SAF and pregnancies complicated by diabetes mellitus, and SAF and macrosomia. GDM diagnosis varies due to the different approaches among the major guidelines, leading to variations in interpretation and diagnostic thresholds. Across studies, this variability contributes to inconsistent SAF values. As a standardized and objective marker, SAF could provide a uniform criterion, improving GDM management. Further research is needed to validate its clinical utility.
- Open Access
Navigating Fertility Preservation Options in Gynecological Cancers: A Comprehensive Review
(1) Background: Currently, an increasing number of women postpone pregnancy beyond the age of 35. Gynecological cancers affect a significant proportion of women of reproductive age, necessitating the development of fertility preservation methods to fulfill family planning. Consequently, providing treatment options that preserve fertility in women diagnosed with gynecological cancers has become a crucial component of care for survivors. (2) Methods: We conducted an extensive search of relevant scientific publications in PubMed and Embase databases and performed a narrative review, including high-quality peer-reviewed research on fertility after being treated for gynecologic cancers, reporting pregnancy rates, birth rates, and pregnancy outcomes in cancer survivors as well as therapeutic options which partially preserve fertility and methods for obtaining a pregnancy in survivors. (3) Discussion: The medicine practiced today is focused on both treating the neoplasm and preserving the quality of life of the patients, with fertility preservation being an important element of this quality. This leads to an improved quality of life, allowing these women to become mothers even in the seemingly adverse circumstances posed by such a pathology. However, although there are guidelines on female fertility preservation in the context of neoplasms, an analysis shows that physicians do not routinely consider it and do not discuss these options with their patients. (4) Conclusions: Advancements in medicine have led to a better understanding and management of gynecological neoplasms, resulting in increased survival rates. Once the battle against these neoplasms is won, the issue of preserving the quality of life for these women arises, with fertility preservation being an important aspect for women who have not yet fulfilled their family planning desires at the time of diagnosis. It is important for patients to be informed about the available options for fertility preservation and to be encouraged to make informed decisions in collaboration with their medical team. Standardized recommendations for onco-fertility into guidelines should be taken into consideration in the future.
Open AccessNavigating Fertility Preservation Options in Gynecological Cancers: A Comprehensive Review
(1) Background: Currently, an increasing number of women postpone pregnancy beyond the age of 35. Gynecological cancers affect a significant proportion of women of reproductive age, necessitating the development of fertility preservation methods to fulfill family planning. Consequently, providing treatment options that preserve fertility in women diagnosed with gynecological cancers has become a crucial component of care for survivors. (2) Methods: We conducted an extensive search of relevant scientific publications in PubMed and Embase databases and performed a narrative review, including high-quality peer-reviewed research on fertility after being treated for gynecologic cancers, reporting pregnancy rates, birth rates, and pregnancy outcomes in cancer survivors as well as therapeutic options which partially preserve fertility and methods for obtaining a pregnancy in survivors. (3) Discussion: The medicine practiced today is focused on both treating the neoplasm and preserving the quality of life of the patients, with fertility preservation being an important element of this quality. This leads to an improved quality of life, allowing these women to become mothers even in the seemingly adverse circumstances posed by such a pathology. However, although there are guidelines on female fertility preservation in the context of neoplasms, an analysis shows that physicians do not routinely consider it and do not discuss these options with their patients. (4) Conclusions: Advancements in medicine have led to a better understanding and management of gynecological neoplasms, resulting in increased survival rates. Once the battle against these neoplasms is won, the issue of preserving the quality of life for these women arises, with fertility preservation being an important aspect for women who have not yet fulfilled their family planning desires at the time of diagnosis. It is important for patients to be informed about the available options for fertility preservation and to be encouraged to make informed decisions in collaboration with their medical team. Standardized recommendations for onco-fertility into guidelines should be taken into consideration in the future.
- Open Access
- 28 March 2024
- Published by MedicHub Media in Ginecologia.ro
- Vol. 1 (1) , 22-24
HTLV: un nou subiect pentru screeningul prenatal?
Human T-cell leukemia virus-1 (HTLV-1) is the first infectious agent proven to cause cancer, and it is considered among the most potent carcinogens for humans. HTLV-1 is estimated to have infected 5-10 million individuals, with only about 5% of people that contract the virus expected to develop any associated disease. Within Europe, Romania appears to be the only region endemic to HTLV-1. There are two primary diseases associated with HTLV-1, T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy (HAM), or tropical spastic paraparesis (TSP). Each is linked to a distinct mode of transmission: ATL with breastfeeding, and HAM/TSP with blood transfusion. The main ways of viral transmission are from mother to child by breastfeeding, via blood transfusions, or through sexual intercourse. Vertical infection rate has been found to be 14.2%. In Romania, HTLV is included in the screening for blood donors, but not in prenatal screenings. Vertically transmitted infections can be reduced with up to 87% by avoiding breastfeeding. New research supports the effectiveness of prenatal screening followed by avoiding breastfeeding in reducing new cases of HTLV in endemic areas, and such measures must be taken in Romania as well.
- 28 March 2024
- Published by MedicHub Media in Ginecologia.ro
- Vol. 1 (1) , 22-24
Open AccessHTLV: un nou subiect pentru screeningul prenatal?
Human T-cell leukemia virus-1 (HTLV-1) is the first infectious agent proven to cause cancer, and it is considered among the most potent carcinogens for humans. HTLV-1 is estimated to have infected 5-10 million individuals, with only about 5% of people that contract the virus expected to develop any associated disease. Within Europe, Romania appears to be the only region endemic to HTLV-1. There are two primary diseases associated with HTLV-1, T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy (HAM), or tropical spastic paraparesis (TSP). Each is linked to a distinct mode of transmission: ATL with breastfeeding, and HAM/TSP with blood transfusion. The main ways of viral transmission are from mother to child by breastfeeding, via blood transfusions, or through sexual intercourse. Vertical infection rate has been found to be 14.2%. In Romania, HTLV is included in the screening for blood donors, but not in prenatal screenings. Vertically transmitted infections can be reduced with up to 87% by avoiding breastfeeding. New research supports the effectiveness of prenatal screening followed by avoiding breastfeeding in reducing new cases of HTLV in endemic areas, and such measures must be taken in Romania as well.
- Open Access
- 31 January 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (3) , 512
The Proper Diagnosis of Thrombophilic Status in Preventing Fetal Growth Restriction
Fetal growth restriction is an important part of monitoring a pregnancy. Because guidelines or diagnostic criteria for either minor or major thrombophilia are scarce, this systematic review aims to summarize the present knowledge in the field. We performed the CRD42022376006 protocol in Prospero with a systematic literature search in PubMed and Web of Science databases and included original full-text articles (randomized control trials and clinical trials) from the last 10 years, published in English, and with the “thrombophilia AND (pregnancy OR diagnostic criteria) AND fetal growth restriction” criteria. After two researchers extracted the articles of interest, they were assessed using the Newcastle–Ottawa Scale and eight articles were included. The elements from the thrombophilia diagnostic predict IUGR, factor V Leiden mutation, MTHFR C667T mutation, protein S deficiency, antithrombin deficiency, factor VII polymorphism, and antiphospholipid antibodies, while the association of protein C, PAI-1 and certain combinations of mutations are still under debate and require the collection of more data. The present systematic review provides an extensive picture of the actual knowledge about thrombophilia diagnosis and its links with pregnancy complications, such as intrauterine growth restriction, despite its limitation in the inclusion of other actually debated disorders such as PAI-1 mutation, protein C deficiency and other thrombophilia types.
- 31 January 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (3) , 512
Open AccessThe Proper Diagnosis of Thrombophilic Status in Preventing Fetal Growth Restriction
Fetal growth restriction is an important part of monitoring a pregnancy. Because guidelines or diagnostic criteria for either minor or major thrombophilia are scarce, this systematic review aims to summarize the present knowledge in the field. We performed the CRD42022376006 protocol in Prospero with a systematic literature search in PubMed and Web of Science databases and included original full-text articles (randomized control trials and clinical trials) from the last 10 years, published in English, and with the “thrombophilia AND (pregnancy OR diagnostic criteria) AND fetal growth restriction” criteria. After two researchers extracted the articles of interest, they were assessed using the Newcastle–Ottawa Scale and eight articles were included. The elements from the thrombophilia diagnostic predict IUGR, factor V Leiden mutation, MTHFR C667T mutation, protein S deficiency, antithrombin deficiency, factor VII polymorphism, and antiphospholipid antibodies, while the association of protein C, PAI-1 and certain combinations of mutations are still under debate and require the collection of more data. The present systematic review provides an extensive picture of the actual knowledge about thrombophilia diagnosis and its links with pregnancy complications, such as intrauterine growth restriction, despite its limitation in the inclusion of other actually debated disorders such as PAI-1 mutation, protein C deficiency and other thrombophilia types.
- Open Access
- 6 January 2023
- Published by MDPI AG in Sustainability
- Vol. 15 (2) , 1069
Nutritional Interventions and Lifestyle Changing in Gestational Diabetes Mellitus Prevention: A Narrative Review
Background: Gestational diabetes mellitus (GDM) is the most common pregnancy complication, and its prevalence is increasing, as obesity is more prevalent in women at reproductive age. Food choices and patterns that might reduce incidence are of great importance, and the present review aims to offer a perspective on different types of nutritional interventions in GDM prevention. Methods: A literature review in the PubMed database was conducted in order to identify full-text, English, randomized control trials and observational clinical studies, published in the last 10 years, that are the most relevant to emphasize the usefulness of nutritional and lifestyle interventions in prevention of GDM. Results and discussions: Twenty-two articles met the inclusion criteria and were relevant for the search. Their outcomes were reported and analyzed. Dietary interventions were very heterogeneous, including general counselling of healthier eating patterns, recommendations to follow a Mediterranean dietary pattern or to choose low-glycemic-index foods, and dietary advice focusing on increasing consumption of some food groups or vitamin D or probiotics supplementations. Conclusions: Among these interventions, a moderate-intensity lifestyle intervention optimizing participants’ consumption of whole grains, vegetables, and fruits; portion control; lowering intake of ultra-processed food and simple sugars; and Mediterranean diet intervention were the most successful in reducing GDM incidence.
- 6 January 2023
- Published by MDPI AG in Sustainability
- Vol. 15 (2) , 1069
Open AccessNutritional Interventions and Lifestyle Changing in Gestational Diabetes Mellitus Prevention: A Narrative Review
Background: Gestational diabetes mellitus (GDM) is the most common pregnancy complication, and its prevalence is increasing, as obesity is more prevalent in women at reproductive age. Food choices and patterns that might reduce incidence are of great importance, and the present review aims to offer a perspective on different types of nutritional interventions in GDM prevention. Methods: A literature review in the PubMed database was conducted in order to identify full-text, English, randomized control trials and observational clinical studies, published in the last 10 years, that are the most relevant to emphasize the usefulness of nutritional and lifestyle interventions in prevention of GDM. Results and discussions: Twenty-two articles met the inclusion criteria and were relevant for the search. Their outcomes were reported and analyzed. Dietary interventions were very heterogeneous, including general counselling of healthier eating patterns, recommendations to follow a Mediterranean dietary pattern or to choose low-glycemic-index foods, and dietary advice focusing on increasing consumption of some food groups or vitamin D or probiotics supplementations. Conclusions: Among these interventions, a moderate-intensity lifestyle intervention optimizing participants’ consumption of whole grains, vegetables, and fruits; portion control; lowering intake of ultra-processed food and simple sugars; and Mediterranean diet intervention were the most successful in reducing GDM incidence.
- Open Access
Diagnosis and Management of Fetal and Neonatal Thyrotoxicosis
Background and Objectives: Clinical fetal thyrotoxicosis is a rare disorder occurring in 1–5% of pregnancies with Graves’ disease. Although transplacental passage of maternal TSH receptor stimulating autoantibodies (TRAb) to the fetus occurs early in gestation, their concentration in the fetus is reduced until the late second trimester, and reaches maternal levels in the last period of pregnancy. The mortality of fetal thyrotoxicosis is 12–20%, mainly due to heart failure. Case report: We present a case of fetal and neonatal thyrotoxicosis with favorable evolution under proper treatment in a 37-year-old woman. From her surgical history, we noted a thyroidectomy performed 12 years ago for Graves’ disease with orbitopathy and ophthalmopathy; the patient was hormonally balanced under substitution treatment for post-surgical hypothyroidism and hypoparathyroidism. From her obstetrical history, we remarked a untreated pregnancy complicated with fetal anasarca, premature birth, and neonatal death. The current pregnancy began with maternal euthyroid status and persistently increased TRAb, the value of which reached 101 IU/L at 20 weeks gestational age and decreased rapidly within 1 month to 7.5 IU/L, probably due to the placental passage, and occurred simultaneously with the development of fetal tachycardia, without any other fetal thyrotoxicosis signs. In order to treat fetal thyrotoxicosis, the patient was administered methimazole, in addition to her routine substitution of 137.5 ug L-Thyroxine daily, with good control of thyroid function in both mother and fetus. Conclusions: Monitoring for fetal thyrotoxicosis signs and maternal TRAb concentration may successfully guide the course of a pregnancy associated with Graves’ disease. An experienced team should be involved in the management.
Open AccessDiagnosis and Management of Fetal and Neonatal Thyrotoxicosis
Background and Objectives: Clinical fetal thyrotoxicosis is a rare disorder occurring in 1–5% of pregnancies with Graves’ disease. Although transplacental passage of maternal TSH receptor stimulating autoantibodies (TRAb) to the fetus occurs early in gestation, their concentration in the fetus is reduced until the late second trimester, and reaches maternal levels in the last period of pregnancy. The mortality of fetal thyrotoxicosis is 12–20%, mainly due to heart failure. Case report: We present a case of fetal and neonatal thyrotoxicosis with favorable evolution under proper treatment in a 37-year-old woman. From her surgical history, we noted a thyroidectomy performed 12 years ago for Graves’ disease with orbitopathy and ophthalmopathy; the patient was hormonally balanced under substitution treatment for post-surgical hypothyroidism and hypoparathyroidism. From her obstetrical history, we remarked a untreated pregnancy complicated with fetal anasarca, premature birth, and neonatal death. The current pregnancy began with maternal euthyroid status and persistently increased TRAb, the value of which reached 101 IU/L at 20 weeks gestational age and decreased rapidly within 1 month to 7.5 IU/L, probably due to the placental passage, and occurred simultaneously with the development of fetal tachycardia, without any other fetal thyrotoxicosis signs. In order to treat fetal thyrotoxicosis, the patient was administered methimazole, in addition to her routine substitution of 137.5 ug L-Thyroxine daily, with good control of thyroid function in both mother and fetus. Conclusions: Monitoring for fetal thyrotoxicosis signs and maternal TRAb concentration may successfully guide the course of a pregnancy associated with Graves’ disease. An experienced team should be involved in the management.